Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.
Emergent BioSolutions Inc. (NYSE: EBS) regularly issues news and updates that reflect its focus on public health threats and pharmaceutical preparation manufacturing. Company announcements highlight developments across its commercial naloxone franchise, medical countermeasures portfolio, manufacturing network and financial performance, providing context for how Emergent pursues its stated mission to protect and save lives.
News items frequently cover product and regulatory milestones, such as U.S. Food and Drug Administration approvals and supplemental applications. Examples include FDA approval of over‑the‑counter NARCAN® Naloxone HCl Nasal Spray 4 mg and approval of a supplemental Biologics License Application for raxibacumab manufacturing at Emergent’s Winnipeg, Canada facility. Releases also describe new packaging options, such as the NARCAN® Nasal Spray carrying case designed to make naloxone easier to carry and more discreet.
Emergent’s news flow also features government contracts and contract modifications for medical countermeasures. Recent announcements describe delivery orders and options to supply BioThrax® (Anthrax Vaccine Adsorbed), ACAM2000® (Smallpox (Vaccinia) Vaccine, Live), CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), TEMBEXA® and BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to U.S. government agencies responsible for preparedness and response.
Investors and observers can also find financial and corporate updates, including quarterly earnings releases, segment performance commentary, debt prepayments under term loan facilities, and notices of presentations at healthcare conferences. Additional news addresses board‑level changes and corporate governance matters.
Other communications focus on public health initiatives and collaborations, such as support for opioid poisoning awareness observances, partnerships aimed at increasing workplace access to naloxone, and collaboration with PANTHER and Africa CDC on the MpOx Study in Africa. Together, these updates offer insight into how Emergent’s products, contracts, research collaborations and financial decisions relate to its role in addressing health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies.
Hikma Pharmaceuticals announces Health Canada's approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg for treating known or suspected opioid overdose in adult patients. The treatment will be marketed in Canada by Emergent BioSolutions under a six-year commercial agreement, with availability expected by 2026.
The 8 mg naloxone hydrochloride nasal spray offers a higher-dose alternative to the existing 4 mg NARCAN® Nasal Spray. This approval comes as Canada faces significant opioid-related challenges, with 22 lives lost daily to overdoses in 2023. However, recent Health Canada data shows a national decrease in overdose deaths for the third consecutive year, partially attributed to expanded naloxone distribution.
Under the agreement, Emergent will handle North American sales and marketing, while Hikma will manufacture the product at its Columbus, Ohio facility. Emergent plans to engage with Canadian agencies, private payers, and provincial formularies to ensure widespread availability.
Emergent BioSolutions (NYSE:EBS) has completed the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International for $36.5 million, subject to post-closing adjustments. The transaction includes the transfer of facility assets and equipment to Syngene.
As part of the agreement, Emergent maintains rights to access manufacturing services and capacity at the facility for future growth and pandemic response production in partnership with Syngene. The company's CEO Joe Papa stated this strategic move aligns with their multi-year transformation efforts to streamline operations while maintaining production flexibility.
Emergent BioSolutions (NYSE: EBS) has secured approximately $27 million in international orders for delivery in 2025 for its medical countermeasures (MCM) portfolio. The orders focus on products addressing potential smallpox and anthrax threats, contributing to international market supply.
Joe Papa, president and CEO, emphasized Emergent's role as a trusted partner in supplying communities with protective medical countermeasures. The company plans to continue its international expansion efforts as part of its multi-year transformation plan, strengthening health preparedness globally.
Emergent specializes in developing, manufacturing, and supplying MCMs for national security and public health preparedness, enabling governments to respond effectively to emergencies and protect against potential threats.
Emergent BioSolutions (NYSE: EBS) is expanding access to NARCAN® Nasal Spray, the first FDA-approved over-the-counter 4 mg naloxone product for opioid overdose emergency treatment. The initiative comes as opioid overdose deaths show their first decline in five years nationwide.
The company is launching two key partnerships:
- Collaboration with NYC Building & Construction Industry Safety Fund to implement HOPE/LIVES program, providing training and emergency kits with two doses of NARCAN® to construction workers, who face higher opioid prescription rates and fatal overdose risks
- Partnership with Pathway Healthcare to supply NARCAN® Nasal Spray across their Mississippi locations, enhancing accessibility in addiction treatment and mental health facilities
These initiatives aim to increase opioid emergency preparedness and reduce barriers to access, while providing education on overdose recognition and proper administration of the life-saving medication.
Emergent BioSolutions (NYSE: EBS) has announced a strategic investment agreement with Rocketvax , a Swiss next-generation vaccine company. The partnership includes Emergent leading U.S. manufacturing and commercialization for four of Rocketvax's pipeline candidates targeting infectious diseases, cancer, and autoimmune disorders.
One of Rocketvax's leading candidates is a live-attenuated nasal spray SARS-CoV-2 vaccine, which has shown superior efficacy compared to mRNA COVID-19 vaccines in animal studies. Rocketvax has already secured a letter of intent with the NIH under Project NextGen initiative for clinical trials of their proprietary technology.
The collaboration aims to combine Rocketvax's innovative vaccine development with Emergent's production capabilities, supporting Emergent's strategic focus on growth and transformation while advancing breakthrough medical technologies.
Emergent BioSolutions (NYSE:EBS) has announced the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International for $36.5 million. The facility includes manufacturing, laboratory, warehousing and office space, equipped with multiple monoclonal antibody manufacturing lines.
As part of the agreement, Emergent will maintain rights to secure manufacturing services and capacity at the facility for future growth and pandemic response production. The company will continue operating facilities in Lansing, Michigan and Winnipeg, Manitoba.
The sale, expected to close in Q1 2025, aligns with Emergent's multi-year transformation plan. Notably, the Bayview site received a 'No Action Indicated' (NAI) status from the FDA in March 2024, indicating favorable inspection outcomes.
Emergent BioSolutions (EBS) reported Q4 2024 financial results with total revenues of $194.7 million and full-year revenues of $1.04 billion. The company posted a Q4 net loss of $31.3 million, representing a 37% improvement from the previous year. Q4 Adjusted EBITDA reached $21.0 million, a 518% increase year-over-year.
Key Q4 performance metrics showed mixed results across segments:
- NARCAN® sales decreased 41% due to lower OTC and Canadian retail sales
- Anthrax MCM products declined 71%
- Smallpox MCM products surged 565%
- Commercial Products segment gross margin fell 57% to $22.4 million
The company completed several strategic initiatives in 2024, including receiving $550 million in Medical Countermeasure Contract awards, repaying $168 million of debt, and completing $117 million in asset divestitures. For 2025, Emergent is guiding Adjusted EBITDA of $150-200 million with improved gross margins.
Emergent BioSolutions (NYSE: EBS) has announced two upcoming investor events. The company will host a conference call on March 3, 2025, at 5:00 pm ET to discuss fourth quarter and full year 2024 financial results. Additionally, company leaders will present at J.P. Morgan's 2025 Leveraged Finance Conference on February 24, 2025, at 11:00 am ET.
Both events will be accessible via webcast through the company's Investors page. For the earnings call, telephone participants must register in advance to receive dial-in details and access credentials. A replay of the earnings call will be available on Emergent's website.
Emergent BioSolutions (NYSE: EBS) is partnering with pro football legend Emmitt Smith to raise awareness of the Ready to Rescue initiative in New Orleans during the Big Game weekend. The campaign focuses on opioid overdose prevention and the use of NARCAN® Nasal Spray.
Despite a national decline in opioid overdose deaths reported by the CDC, New Orleans continues to face increasing drug-related deaths. In 2022, drug-related overdose deaths were nearly double the number of homicides in the city. The campaign features Smith in a 'Lay, Spray, Stay' educational video demonstrating NARCAN® administration, which will be displayed on local taxi television screens throughout the city.
The initiative coincides with New Orleans hosting approximately 83,000 fans for the Big Game. Hundreds of NARCAN® Nasal Spray cartons will be distributed in the city during the weekend. The campaign aims to reduce stigma around accidental opioid poisonings and educate communities on life-saving interventions.
Africa CDC has initiated patient enrollment in the MOSA trial, a pan-African randomized platform adaptive study for Mpox treatment at Mbandaka Hospital in DRC. The study, primarily evaluating brincidofovir, comes as Mpox remains a significant health threat across Africa, particularly affecting vulnerable populations.
The trial follows recent studies (PALM 007 and STOMP) showing tecovirimat's effectiveness in lesion resolution. MOSA will assess different antivirals' safety and efficacy, starting with brincidofovir, an antiviral from Emergent BioSolutions currently available in the US under emergency use IND for Mpox.
The study protocol includes a two-week treatment period with either brincidofovir or placebo in liquid oral form, administered weekly. The first interim analysis is expected by Q1 2025. The trial, sponsored by PANTHER and initially funded by EU's Horizon Europe program, will recruit both children and adults, focusing on those at highest risk of severe outcomes.